A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

被引：2

作者：

Idowu, Modupe ^{[1
]}

Otieno, Lucas ^{[2
]}

Dumitriu, Bogdan ^{[3
]}

Lobo, Clarisse L. C. ^{[4
]}

Thein, Swee Lay ^{[5
]}

Andemariam, Biree ^{[6
]}

Nnodu, Obiageli E. ^{[7
]}

Inati, Adlette ^{[8
]}

Glaros, Alexander K. ^{[9
]}

Olalla Saad, Sara Teresinha ^{[10
,11
]}

Bartolucci, Pablo ^{[12
]}

Colombatti, Raffaella ^{[13
]}

Taher, Ali T. ^{[14
]}

Abboud, Miguel R. ^{[15
]}

Oluyadi, Abdulafeez ^{[16
]}

Iyer, Varsha ^{[16
]}

Yin, Ophelia ^{[17
,18
]}

Morris, Susan ^{[16
]}

Yates, Amber M. ^{[16
]}

Shao, Hui ^{[16
]}

Patil, Spurthi ^{[16
]}

Urbstonaitis, Rolandas ^{[16
]}

Zaidi, Ahmar U. ^{[16
]}

Smith, Wally R. ^{[19
]}

机构：

[1] UTHealth, McGovern Med Sch, Houston, TX USA

[2] Victoria Biomed Res Inst, Kisumu, Kenya

[3] Mid Atlantic Permanente Med Grp, Largo, MD USA

[4] HEMORIO, Div Res, Rio De Janeiro, Brazil

[5] NHLBI, Sickle Cell Branch, Bethesda, MD USA

[6] Univ Connecticut Hlth, New England Sickle Cell Inst, Farmington, CT USA

[7] Univ Abuja, Dept Haematol & Blood Transfus, Coll Hlth Sci, Ctr Excellence Sickle Cell Dis Res & Training, Abuja, Nigeria

[8] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Byblos & NINI Hosp, Tripoli, Lebanon

[9] Childrens Hosp Michigan, Div Hematol Oncol, Detroit, MI USA

[10] Univ Estadual Campinas, Hematol & Transfus Med Ctr, Hemoctr, Campinas, SP, Brazil

[11] Univ Campinas Unicamp, Campinas, Brazil

[12] Mondor Univ Hosp, Reference Ctr Sickle Cell Dis, Creteil, France

[13] Univ Padua, Pediat Hematol Oncol Unit, Padua, Italy

[14] Amer Univ Beirut, Med Ctr, Beirut, Lebanon

[15] Amer Univ, Dept Pediat & Adolescent Med, Beirut Med Ctr, Beirut, Lebanon

[16] Agios Pharmaceut Inc, Cambridge, MA USA

[17] ITeos Therapeut, Watertown, MA USA

[18] Agios Pharmaceut Inc, Time Res, Cambridge, MA USA

[19] Virginia Commonwealth Univ, Richmond, VA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] Talactoferrin Alfa Reduces Mortality In Severe Sepsis: Results Of A Phase 2 Randomized, Placebo-controlled, Double-blind Study
Guntupalli, K. K.
Dean, N. C.
Morris, P. E.
Bandi, V.
Margolis, B. D.
Rivers, E.
Levy, M. M.
Lodato, R. F.
Schaumberg, J.
Malik, R. K.
Dellinger, P.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
[42] Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Sakaida, Isao
Kawazoe, Seiji
Kajimura, Kozo
Saito, Takafumi
Okuse, Chiaki
Takaguchi, Koichi
Okada, Mitsuru
Okita, Kiwamu
HEPATOLOGY RESEARCH, 2014, 44 (01) : 73 - 82
[43] A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis
Bissonnette, R
Papp, K
Poulin, Y
Lauzon, G
Aspeslet, L
Huizinga, R
Mayo, P
Foster, RT
Yatscoff, RW
Maksymowych, WP
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : 472 - 478
[44] Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
Motoya, Satoshi
Watanabe, Kenji
Ogata, Haruhiko
Kanai, Takanori
Matsui, Toshiyuki
Suzuki, Yasuo
Shikamura, Mitsuhiro
Sugiura, Kenkichi
Oda, Kazunori
Hori, Tetsuharu
Araki, Takahiro
Watanabe, Mamoru
Hibi, Toshifumi
PLOS ONE, 2019, 14 (02):
[45] Safety and tolerability of twice-daily balsalazide tablets: Results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study
Pruitt, Ronald E.
Rosen, Alan A.
Wruble, Lawrence
Sedghi, Shahriar
Shepard, Roland D.
Mareya, Shadreck M.
Huang, Shirley
Shaw, Audrey L.
Forbes, William F.
GASTROENTEROLOGY, 2008, 134 (04) : A494 - A494
[46] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
Papp, K
Mease, P
Garovoy, M
Zhang, D
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
[47] Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Crohn's Disease
Chowla, Navreet M.
Tariq, Raseen
Aggarwal, Manik
Loftus, Edward V.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10) : S820 - S821
[48] Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Slatkin, Neal
Zaki, Naim
Wang, Steven
Louie, John
Sanga, Panna
Kelly, Kathleen M.
Thipphawong, John
JOURNAL OF PAIN, 2019, 20 (04) : 440 - 452
[49] Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-blind, Placebo-Controlled PSUMMIT I Study
Rahman, Proton
Kavanaugh, Arthur
Gottlieb, Alice
Puig, Lluis
Ritchlin, Christopher
McInnes, Iain
Li, Shu
Wang, Yuhua
Mendelsohn, Alan
Doyle, Mittie
JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 983 - 983
[50] Results from PIONEER: A randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM)
Maurer, M.
Elberink, H. O.
Gotlib, J.
Sabato, V.
Hartmann, K.
Broesby-Olsen, S.
Castells, M.
Deininger, M. W.
Heaney, M. L.
George, T. I.
Siebenhaar, F.
Radia, D.
Triggiani, M.
van Daele, P.
Deangelo, D. J.
Schmidt-Kittler, O.
Lin, H. -M.
Morrison, A.
Mar, B.
Akin, C.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 77 - 77

← 1 2 3 4 5 →